MVA-BN Vaccine Effectiveness: A Systematic Review of

2 Real-World Evidence in Outbreak Settings

3 Authors:

- 4 Lauren M.K. Mason Ph.D.^a, Estefania Betancur MSc^a, Margarita Riera-Montes MD MSc^a, Florian
- 5 Lienert Ph.D.^b, Suzanne Scheele MS^c

6 Affiliations:

- ^a P95 Epidemiology and Pharmacovigilance, Leuven, Belgium.
- 8 ^b Bavarian Nordic Switzerland AG, Zug, Switzerland
- ⁹ ^c Bavarian Nordic, Inc., Morrisville, North Carolina, United States of America.

Corresponding author: Florian Lienert; Bavarian Nordic Switzerland AG, Zug, Switzerland;
 flli@bavarian-nordic.com

12 Abstract

Background: Mpox is a disease endemic to Central and West Africa. It caused outbreaks in nonendemic countries, mainly in 2022. The endemic Democratic Republic of Congo is currently experiencing its largest outbreak yet. The vaccine Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) is approved for active immunization against mpox and smallpox. Since the outbreak in 2022, realworld studies have assessed MVA-BN's vaccine effectiveness (VE) against mpox, and this systematic literature review aims to summarize the most current evidence.

Methods: Medline (via PubMed), Embase, and LILACS were searched, as well as grey literature sources and publications' bibliographies to identify observational studies published between 1/Jan/2022 and 28/Feb/2024 that estimate the VE of MVA-BN against symptomatic mpox or provide risk measures that allow calculation of these VE estimates. Data were presented descriptively in tables and text; the methodological quality of included records was assessed using an informal qualitative approach.

25 Results: The literature search identified a total of 16 records that fit the inclusion criteria. The studies 26 took place in high-income countries and were heterogenous in design, setting, and definition of at-risk 27 populations. MVA-BN VE estimates against symptomatic mpox infection ≥14 days post-vaccination 28 were assessed. Where the study population was exclusively or primarily those receiving pre-exposure 29 prophylactic vaccination, the adjusted VE estimates ranged from 35% to 86% (n=8 studies) for one dose and from 66% to 90% (n=5) for two doses. Where only post-exposure prophylactic vaccination 30 31 was assessed, adjusted VE estimates were reported for one dose only at 78% and 89% (n=2). 32 Additionally, MVA-BN reduced the risk of mpox-related hospitalization in one study and the severity of 33 mpox clinical manifestations in two studies.

34 **Conclusions**: Despite heterogeneity in study design, setting, and at-risk populations, the reported VE

35 estimates against symptomatic mpox infection for one or two doses of MVA-BN support deployment of

36 MVA-BN for mpox outbreak control.

37 Keywords

mpox; post-exposure prophylactic vaccination; pre-exposure prophylactic vaccination; real-world
 evidence; systematic literature review; vaccine effectiveness

40 **Abbreviations**

CDC: US Centers for Disease Control and Prevention; CDESS: The Communicable Disease 41 42 Electronic Surveillance System; CHS: Clalit Health Services; CI: confidence interval; DE: data 43 extraction; DRC: Democratic Republic of Congo; FT: full-text review; GBMSM: gay, bisexual, and 44 other men who have sex with men; HIV: human immunodeficiency virus; HRR: hazard rate ratio; IC, 45 immunocompromised; IRR: incidence rate ratio; MeSH: medical subject headings; MPVX: monkeypox virus; MSM: men who have sex with men; MVA-BN: Modified Vaccinia Ankara-Bavarian Nordic; NR: 46 47 not reported; NYC: New York City; OCM: other clinical manifestations; OR: odds ratio; PDE5: phosphodiesterase 5; PEP: post-exposure prophylactic vaccination; PrEP: pre-exposure prophylactic 48 49 vaccination; PICOS: patient, intervention, comparison, outcome, setting; PRISMA: Preferred 50 Reporting Items for Systematic Reviews and Meta-Analyses; RR: risk ratio; RWE: real-world 51 evidence; SHC: sexual health clinic; SLR: systematic literature review; STI: sexually transmittable 52 infection; SVI: social vulnerability index; VE: vaccine effectiveness.

53 Introduction

66

54 Mpox, formerly called monkeypox and first described in humans in the Democratic Republic of Congo 55 (DRC) in 1970 [1], is an illness that was initially zoonotic and is caused by the monkeypox virus 56 (MPXV). This DNA virus belongs to the Orthopoxvirus genus, which also includes the smallpox-57 causing variola virus [2]. The clinical presentation of mpox includes a distinctive, extensive rash, fever, 58 headache, cough, asthenia, and lymphadenopathy. Additionally, complications such as coalescence 59 of skin ulcers, bacterial skin infections, bronchopneumonia, and sepsis may occur [3]. MPXV is 60 transmitted from animals to humans and between humans through contact with bodily fluids, lesions on the skin or mucosae, respiratory droplets, and contaminated objects [4]. A definitive animal 61 62 reservoir host has not been identified [1]. 63 Before the unprecedented global spread of the disease outside previously endemic countries in 2022, 64 reports of mpox were almost exclusively limited to Central and West African countries [4]. An 65 observed increase in cases in these countries before 2018 was hypothesized to be due to the

Starting in May 2022, a significant surge in mpox cases occurred in numerous non-endemic countries 67 68 [5]. As of February 2024, over 94,000 confirmed mpox cases have been documented in 117 countries 69 [6]. While previous occurrences of mpox in non-endemic regions were associated with international 70 travel and importation of infected animals from West Africa [7], the 2022 outbreak was primarily 71 characterized by human-to-human transmission of MPXV [8]. This outbreak mainly occurred among, but was not limited to, men who have sex with men (MSM) and in several high-income countries [9], 72 73 which had not been reported previously. Other differences included a different clade type, lower 74 mortality, and suggested novel epidemiological and clinical characteristics [9]. The outbreak response 75 strategy consisted mainly of behavior change and vaccination of high-risk populations [2].

cessation of routine smallpox vaccination leading to waning Orthopoxvirus immunity [1].

The DRC is currently experiencing its largest ever recorded mpox outbreak, with more than 12,000 suspected cases and 500 deaths reported since the start of 2023 [10]. The outbreak is spreading to almost all provinces, with different transmission patterns and affected populations. Some areas are seeing large-scale transmission involving a larger proportion of children, potentially due to contact with rodents. The province of Equateur, with a population of almost 6 million, is experiencing large, concomitant mpox and measles outbreaks, with a potential increase in the risk of complications and a

larger reported mortality rate, as well as the risk of misdiagnosis of either disease. There is also a large outbreak of primarily sexually transmitted mpox infections among sex workers and adults in the mining city of Kamituga in South Kivu. The city's highly mobile population creates the risk for a multicountry outbreak as the area borders Rwanda, Burundi, and Tanzania [11]. Global outbreak response teams from multiple countries are active in the DRC, and mpox vaccination may soon become a tool in controlling the current crisis.

Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN; trade names Jynneos/Imvanex/Imvamune) is the smallpox and mpox vaccine that has most broadly been used in response to the global mpox outbreak. MVA-BN cannot replicate in human cells and, unlike replicating smallpox vaccines, has a favorable safety profile for individuals with atopic dermatitis and immunodeficiency [12].

92 The MVA-BN vaccine can be administered prophylactically either before or after exposure to 93 confirmed mpox cases. Pre-exposure prophylactic vaccination (PrEP) aims at protecting those at risk 94 of mpox infections prior to having had contact with a confirmed case. Currently, the US Centers for 95 Disease Control and Prevention (CDC) recommends PrEP for the at-risk groups: those at risk of 96 occupational exposure, gay, bisexual, and other MSM (GBMSM) who have been diagnosed with 97 certain sexually transmitted diseases and have multiple sexual partners, individuals engaging in 98 sexual activities in areas with a high prevalence of mpox, and those with sexual partners meeting these criteria, as well as people with human immunodeficiency virus (HIV) infection or other causes of 99 100 immunosuppression who have had recent or anticipate potential mpox exposure [13]. Post-exposure 101 prophylactic vaccination (PEP) aims to prevent mpox or reduce its severity in individuals who have 102 had contact with confirmed cases and can be administered up to 14 days post-exposure [13].

103 The regulatory authorities in the US, Canada, UK, and the EU approved MVA-BN in a two-dose 104 schedule ≥28 days apart for active immunization against smallpox and mpox based on pre-clinical efficacy data from animal studies and clinical immunogenicity and safety studies [14-17]. The efficacy 105 106 of MVA-BN against mpox has not been demonstrated in randomized controlled clinical trials; however, 107 since the 2022 outbreak started, several real-world effectiveness studies have been conducted. This 108 systematic literature review (SLR) aims to identify and summarize the most current real-world 109 evidence (RWE) on the MVA-BN vaccine effectiveness (VE) against symptomatic mpox infection, 110 mpox-related hospitalization, and severity of clinical mpox manifestations.

111 Methods

112 Registration and protocol

- 113 This SLR was registered prospectively in PROSPERO (<u>https://www.crd.york.ac.uk/prospero/;</u> number
- 114 CRD42023441204), where key features from the protocol can be retrieved. The literature search was
- initially performed in 2023 and updated on February 28, 2024, to include the latest relevant literature.
- 116 The focus of this manuscript is on the summary of RWE of the VE of MVA-BN against mpox.
- 117 The protocol and manuscript for this SLR were developed in line with recommendations from the 118 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement and 119 PRISMA extension for protocols (PRISMA-P) [18, 19].

120 Search strategies and eligibility criteria

121 The databases Medline (via PubMed), Embase, and LILACS were searched using database-specific 122 keywords and medical subject headings (MeSH terms) related to mpox and vaccine 123 effectiveness/vaccination. The detailed search strategies are available in Supplementary Methods. 124 We included peer-reviewed publications reporting on observational studies in humans on the VE of 125 MVA-BN, published between January 1, 2022, and February 28, 2024 (date of last search) in English, 126 Spanish, or French. We excluded publications that did not meet the inclusion criteria or where 127 methods and sources for data collection and/or analysis were not clearly defined. Records reporting 128 on in vitro studies, modeling studies, case reports/series, and (non-)randomized clinical trials were 129 excluded. SLRs and meta-analyses (MAs) were retained through the search and first selection stage 130 to allow screening through the bibliographies for identification of additional relevant publications, but 131 SLRs and MAs were not retained for data extraction. The full list of eligibility criteria is available in 132 Supplementary Methods.

To identify additional relevant publications, grey literature sources and pre-print databases were searched on March 5, 2024 (date of last search) using source-specific search terms and limits as detailed in **Supplementary Methods**.

136 Record selection

After deduplicating identified records, two independent researchers (EB, LM) screened the titles and abstracts of all records in duplicate. Results were compared and discrepancies were discussed; in

139 case of doubt, the record was included for full-text review. Records for which insufficient information 140 was available in the title and abstract were also included for full-text review. All full texts were 141 reviewed by one researcher (EB), and full texts for 10% of the records were screened in duplicate 142 (EB, LM). The results were compared and discrepancies were discussed; any doubts outside the 10% 143 were also discussed. When multiple articles reported on the same dataset and the same outcome, 144 only the most recent and complete available version was included. To identify additional relevant 145 publications, bibliographies of selected papers (e.g., key studies, SLRs, and MAs) were manually 146 searched.

147 Data collection and synthesis

148 One reviewer (EB) extracted all relevant data for each retained record in a pre-defined template in 149 Microsoft Excel. The main outcomes of interest were crude and/or adjusted VE estimates against 150 symptomatic mpox infection, mpox-related hospitalization, and severity of mpox clinical 151 manifestations with crude/adjusted confidence intervals (CIs). Data related to these VE estimates, 152 such as VE calculation methods, subpopulations, stratification groups, incidence rates, cumulative 153 hazard rates, risk association measures (odds ratios [ORs], risk ratios [RRs], hazard ratios [HRs], 154 incidence rate ratios [IRR], hazard rate ratios [HRRs]), and confounders were also extracted. In case 155 no crude or adjusted VE estimates were reported in the publication, we calculated the VE and 95% 156 Cls from extracted risk association measures using the following formula:

$$VE = 1 - \frac{Risk among vaccinated group}{Risk among unvaccinated group} \times 100$$

No other calculations or assumptions were made in case of other missing data. Variables related to study characteristics (e.g., study design, vaccination strategy), population characteristics (e.g., sample definitions, comorbidities), study methods (e.g., case and control definitions), additional information on statistical analyses (e.g., results of the sensitivity analysis), and data for assessment of the study's methodological quality (e.g., strengths and limitations as mentioned by the authors) were also extracted.

163 Study characteristics and the collected VE estimates were presented descriptively in tables and text. 164 VE estimates were reported stratified by type of vaccination strategy: PrEP or PEP. For the former, we 165 reported studies including exclusively PrEP recipients together with studies designed primarily to

evaluate PrEP, but that may have inadvertently included some PEP subjects (designated 'PrEP ± PEP'). Due to the heterogeneity of the data, no statistical synthesis of the extracted data was performed.

169 **Risk of bias assessment**

The methodological quality of all records included in the final review was assessed by three researchers (EB, LM, MRM) using an informal qualitative approach based on the expertise of reviewers and published commentaries, as well as the limitations described by the authors themselves. Potential biases of the studies were identified and how these might impact the results and conclusions of the studies was considered and discussed.

175 **Results**

176 Study selection and characteristics

The literature search identified 904 unique records from databases, of which 106 were retained for full-text review and eight were included in the final review. Nine additional records were identified from other sources, of which eight were included in the final review. Hence, a total of 16 records on 16 unique studies were identified that reported on the VE of MVA-BN against symptomatic mpox infection or provided risk measures that allow calculation of VE estimates (**Figure 1**).

182 The main characteristics of the included studies are summarized in **Table 1**. The studies took place in 183 six countries, with the majority conducted in the United States (n=7) [20-26], followed by Canada 184 (n=3) [27-29], Spain (n=2) [30, 31], the United Kingdom (n=2) [32, 33], and one each in Israel [34] and 185 the Netherlands [35]. The studies used various designs to assess effectiveness of MVA-BN, with a 186 retrospective cohort design being used most frequently (n=6) [23, 24, 26, 27, 30, 34], followed by a 187 case-coverage design (n=4) [22, 32, 33, 35], a case-control design (n=4; incl. one test-negative case-188 control design [28]) [20, 21, 25, 28], and a prospective cohort design (n=2) [29, 31]. The studies used 189 linked data from public health surveillance systems [20, 22-30, 32, 33], from public health institutions 190 [23, 31, 35], and/or from healthcare systems [21, 34]. The number of mpox cases included for 191 calculation of the VE against symptomatic mpox infection ranged from 137 to 11,320. Control groups 192 were defined in various ways across study designs and included MSM, incident HIV cases, males 193 with sexually transmitted infections (STIs), symptomatic individuals who tested negative for mpox, and 194 individuals in contact with mpox cases. The study period covered (part of) 2022 in 11 studies [21-25,

195 28, 30-32, 34, 35], (part of) 2022 and part of 2023 in four studies [20, 26, 27, 29], and the whole of 196 2023 in one study [33]. Fourteen studies focused on the use of MVA-BN as PrEP, of which six 197 included PrEP recipients only [21, 28-30, 32, 33] and eight may have included a proportion of PEP 198 recipients due to the available data not allowing exclusion of all PEP recipients (PrEP ± PEP) [20, 22, 199 23, 25-27, 34, 35]; the remaining two studies focused on the use of MVA-BN as PEP [24, 31]. The 198 effectiveness of MVA-BN against mpox was evaluated using ORs (n=10) [20, 21, 24-28, 32, 33, 35], 199 HRs (n=4) [23, 29, 31, 34], RRs (n=1) [30], or IRRs (n=1) [22] (Table 1).

202 Risk of bias

- 203 The risk of bias assessment found sources of (residual) confounding in several studies, with the most
- 204 important ones resulting from the overall population setting and/or the selection of
- 205 controls/comparator groups [21, 23-28, 31-34]. Sources of bias inherent to study design were also
- identified, including misclassification bias for studies using data from registries and databases [24, 25,
- 207 33], recall bias and non-response bias for studies using surveys and self-reported data [20, 24, 27,
- 208 28, 32], and an inability to control for confounders in case-coverage studies [22, 32, 33, 35].
- Additionally, one study was found to be at risk of immortal time bias [31].

210 Study results

211 Vaccine effectiveness estimates against symptomatic mpox infection for PrEP with MVA-BN

212 Twelve studies reported that PrEP with MVA-BN reduced the risk of symptomatic mpox infection at

213 ≥14 days after vaccination. Half of the studies reported data for PrEP recipients only, while the other

214 half may have included a proportion of PEP recipients (PrEP ± PEP). Five studies reported data for

one dose of MVA-BN only, one study reported data for two doses only, and six studies reported data

for both one and two doses (**Table 2**).

For one dose of MVA-BN administered as PrEP, adjusted VE estimates between 35% and 86% were reported across eight studies. Seven studies reported crude VE estimates, which fell within the same range (33%–84%). The studies conducted by Brousseau et al. [28] and Deputy et al. [21] reported adjusted VE estimates for one dose of MVA-BN of 35% and 36%, respectively, which were notably lower than the adjusted VE estimates reported in the other studies (≥59%) (**Table 2**).

For two doses of MVA-BN administered as PrEP, five studies reported adjusted VE estimates ranging from 66% to 90%. The reported crude VE estimates ranged from 57% to 87% in five studies (**Table**

224 2). The study by Charles et al. [33] was the only study to use data collected in the year 2023 (Jan 2023 until Dec 2023) only, and found crude VE estimates of 84% for one dose and 80% for two doses
226 of MVA-BN (adjusted VE estimates were not reported) (Table 2).

227 Vaccine effectiveness estimates against symptomatic mpox infection for PEP with MVA-BN

228 Two studies reported on the effectiveness of one dose of PEP with MVA-BN against symptomatic

229 mpox infection at ≥14 days after vaccination; no data were reported for two doses of PEP (Table 3).

The two studies found adjusted VE estimates of 78% and 89% when 'classic statistical methods' (multivariate logistic regression and survival analysis, respectively) were used. Rosen et al. [24] also calculated VE estimates using target trial emulation to account for immortal time bias, which were -7% for PEP administered \leq 14 days after first exposure and 19% for PEP administered \leq 14 days after last exposure; these VE estimates were associated with wide CIs due to small sample sizes (**Table 3**).

235 Vaccine effectiveness estimates of MVA-BN against mpox-related hospitalization and severity

236 of mpox clinical manifestations

The study by Schildhauer et al. [26] reported a lower risk of mpox-related hospitalization among those who had been vaccinated with MVA-BN compared to those who had not been vaccinated. Based on ORs provided by Schildhauer et al., we calculated crude VE estimates against hospitalization of 73% and 80% for a vaccination schedule consisting of one or two MVA-BN doses, respectively, and 58% for one dose of MVA-BN administered as PEP <14 days before the episode date (**Table 4**).

242 Two papers reported a decreased severity of mpox clinical manifestations in cases who had received 243 one dose of MVA-BN. Allard et al. [27] found adjusted VE estimates at day 1 of infection of 60% 244 against the number of skin lesions, 76% against the number of body sites affected by skin lesions, 245 and 59% against other clinical manifestations (incl. fever, muscle pain, and headache). Montero 246 Morales et al. [31] reported adjusted VE estimates of one dose of MVA-BN administered as PEP of 247 72% against general symptoms (fever, asthenia, odynophagia, muscle pain, headache, or other 248 symptoms) and 86% against polysymptomatic disease (i.e., occurrence of four or more general 249 symptoms) (Table 4).

Vaccine effectiveness estimates of MVA-BN against symptomatic mpox infection by route of administration

Two studies reported data stratified by route of administration; one reported VE estimates while the other study only reported the number of mpox cases in vaccinated and unvaccinated groups (**Supplementary Table 1**). When adjusted VE estimates against symptomatic mpox infection were reported, these were in similar ranges for two doses of MVA-BN regardless of the route of administration: 80% (95% CI 23–95) for intradermal administration, 89% (95% CI 56–97) for subcutaneous administration, and 87% (95% CI 69–95) when administered via a combination of both routes (**Supplementary Table 1**).

Vaccine effectiveness estimates of MVA-BN against symptomatic mpox infection <14 days after vaccination

Four studies reported VE estimates stratified by time after vaccination, and as such demonstrated the
risk of breakthrough infections before the onset of vaccine-induced immunity (Supplementary Table
2). Within the first 13 days post-vaccination, reported VE estimates for MVA-BN PrEP or 'PrEP ± PEP'
did not exceed -4% (95% CI -50–29) (Supplementary Table 2).

265 **Discussion**

266 This SLR identified 16 records on real-world studies assessing the VE of one or two doses of MVA-BN 267 against symptomatic mpox infection, mpox-related hospitalization, and severity of mpox clinical 268 manifestations. When MVA-BN was administered as PrEP, the adjusted VE estimates against 269 symptomatic mpox infection ≥14 days post-vaccination were ≥35% (n=8 studies) for one dose and 270 ≥66% (n=5) for two doses. The lower limit of the VE range for one dose of MVA-BN administered as 271 PrEP was lower than that of other ranges because two studies reported VE estimates that were 272 notably lower than other estimates [21, 28]. Outside of these data points, the adjusted VE estimates 273 for PrEP with one dose of MVA-BN were ≥59%. Adjusted VE estimates against symptomatic mpox 274 infection for MVA-BN administered as PEP were only reported for one dose and were ≥78% (n=2 275 studies). The VE estimates for two doses of MVA-BN fell in a similar range as VE estimates 276 historically reported for replicating vaccinia-based smallpox vaccines [36]. Furthermore, MVA-BN 277 vaccination reduced the risk of mpox-related hospitalization and the severity of mpox clinical 278 manifestations.

279 In most studies, controls or unvaccinated comparator groups were selected based on characteristics 280 such as MSM or transgender status, recent diagnosis of HIV or other STIs, and/or use of HIV pre-281 exposure prophylaxis. However, there was notable heterogeneity across studies in the definition of 282 the at-risk population, which might have influenced the VE estimates. In the case-control study by 283 Deputy et al. [21] for example, which found an adjusted VE estimate against symptomatic mpox 284 infection of 36% for one dose of MVA-BN administered as PrEP and was one of the notably low VE 285 estimates, controls were identified from a large secondary database that may not have had as 286 granular information on risk proxies as studies using individual patient-level data. The control 287 population was not restricted to MSM, resulting in a broader at-risk population than in other studies, 288 which may have led to the inclusion of a higher proportion of subjects who were not vaccine-eligible in 289 the control group and to the underestimation of the VE. This concern was also highlighted in a letter to 290 the editor related to this article [37, 38]. The authors of this letter to the editor highlighted that the 291 vaccine uptake of one dose of MVA-BN among controls reported by Deputy et al. (14.5%) was lower 292 than vaccine uptake data reported by e.g., the CDC. When they recalculated VE estimates against 293 symptomatic mpox infection using a vaccine uptake of 45.5% (i.e., uptake reported by CDC for the 294 period until October 1, 2022 [22]), the crude VE estimate increased to fall within a similar range as VE 295 estimates reported by other studies [22, 32, 34]. A very different approach regarding the included at-296 risk population was taken in the case-control study by Rosenberg et al. [25], where controls were 297 restricted to MSM who had rectal gonorrhea or primary syphilis diagnosed within the same time frame 298 as the mpox cases. This approach was assumed to lead to a control population that exhibited risk 299 behavior similar to the cases within the same time period. A sensitivity analysis within that study 300 included secondary syphilis cases in the control group and found a VE estimate for one or two MVA-301 BN doses against symptomatic mpox infection that trended lower than the main VE estimate, albeit 302 with overlapping CIs (64.8% [95% CI 26.7-83.1] and 75.7% [95% CI 48.5-88.5], respectively). This 303 difference may reflect the inclusion of control patients with more remote risk behaviors or different 304 clinical presentations [25]. As a last example, the test-negative case-control study by Brousseau et al. 305 [28] found a VE estimate against symptomatic mpox infection for one MVA-BN dose of 35% based on 306 data in administrative databases only, with adjustment for surrogate indicators of exposure risk 307 available in these databases. However, when the authors adjusted for self-reported risk factors, which 308 were higher in number and more detailed than those available in the administrative databases, the VE

estimate increased to 65% (with a wide CI) [28]. Though the sample size in this study was small,
particularly for the sub-analysis (n=199 cases), the study design highlights the potential impact of
confounding based on differential risk exposure by vaccination status.

312 Licensure of MVA-BN for protection against mpox was based on the efficacy of two MVA-BN doses 313 against mpox observed in animal studies [39] and clinical safety and immunogenicity data. The latter 314 includes the demonstration of non-inferior immunogenicity compared to the replicating-vaccinia 315 vaccine ACAM2000 together with a more favorable safety profile for MVA-BN compared to 316 ACAM2000 as demonstrated in a pivotal phase 3 randomized clinical trial [40]. While one dose of 317 MVA-BN was previously shown to induce low titers of vaccinia-specific and MPVX-specific 318 neutralizing antibody titers [41-43], our SLR found VE estimates against symptomatic infections for 319 one dose of MVA-BN suggestive of high effectiveness. This challenges the view that neutralizing 320 antibody levels correlate with protection against Orthopoxvirus infection. Indeed, previous 321 experiments showed that MVA vaccination fully protected B cell-deficient mice in Orthopoxvirus 322 challenge models, indicating that antibodies are not the sole correlate of protection [44]. Furthermore, 323 a study including a small number of MVA-BN vaccinated individuals revealed that the protective 324 immunogenicity of MVA-BN might be mostly mediated by T cells [45]. While a correlate of immunity for 325 MVA-BN has not been established yet, these findings suggest that cellular immunity could be 326 relevant. However, a pre-clinical animal study for an mRNA mpox vaccine candidate found that 327 protection was primarily conferred by inducing a focused humoral immune response [46], which 328 suggests that the correlate of immunity might depend on the vaccine platform.

329 This SLR employed a thorough process searching three literature databases combined with grey 330 literature sources including preprints and a search through bibliographies of selected papers. 331 Nevertheless, the presented data need to be interpreted in light of the high heterogeneity across 332 included studies in terms of study design, characteristics of study populations, and study settings, 333 among others, which limits comparisons. Because we considered that this heterogeneity across 334 studies would hamper the interpretation of VE point estimates originating from MAs, we chose not to 335 perform such analysis. This SLR also highlighted gaps in data. Most participants included in the 336 identified studies were adult MSM, and data on females and children are lacking. The use of very 337 specific at-risk groups reduced the generalizability of some studies. All identified studies took place in 338 high-income countries, while no data from mpox-endemic countries were identified. Furthermore,

339 several research groups initiated prospective studies in high-income countries in the early phases of 340 the mpox outbreak, but these have not (yet) been finalized and/or published, primarily because of a 341 waning number of cases. Most of these studies have now been suspended due to a lack of cases. 342 Lastly, while we identified studies that demonstrated the risk of breakthrough infections within 14 days 343 of vaccination, data on VE durability in real-world settings was limited. Only the study by Charles et al. 344 from the UK provided some insight by reporting crude VE estimates against symptomatic infections of 345 84% and 80% for one and two doses of MVA-BN, respectively, based on confirmed and highly 346 probable mpox diagnoses reported until December 2023, while most vaccines had been administered 347 by March 2023 [33]. It should, however, be noted that follow-up time might impact VE estimates as a 348 large proportion of those vaccinated will receive the vaccine during the early stages of its availability 349 during an outbreak. Also, a larger proportion of those at greatest risk of infection are also likely to be 350 infected earlier in the outbreak when awareness and vaccination coverage are lower. Therefore, a 351 longer duration of follow-up may bias toward vaccine effect as overall case rates decline over time.

352 The included studies themselves also had limitations. A common limitation was that, due to the timing 353 of the vaccination program within the mpox outbreak, limited numbers of cases were available for 354 inclusion, especially after deployment of the second MVA-BN dose. This limited the studies in terms of 355 power and the types of analyses that they could perform. However, all of the included studies were 356 adequately powered for primary VE analyses. Furthermore, the studies were inconsistent in how they 357 defined the use of MVA-BN as PEP and whether studies that focused on PrEP included or excluded 358 PEP use in their analyses. The inclusion of a proportion of PEP recipients was unavoidable in some 359 studies because of the data used for the analyses. In Germany, only 7% of all MVA-BN 360 administrations from June 2022 to January 2024 were PEP [47]. Because the studies included in our 361 SLR used mpox vaccination recommendations similar to those in place in Germany, it is likely that the 362 majority of vaccine recipients included in 'PrEP ± PEP' studies received MVA-BN as PrEP. Lastly, all 363 studies were found to be at risk of some (residual) confounding and other sources of bias. Many 364 studies relied on data from databases, and exposure risk was defined based on proxies such as MSM 365 or transgender status, recent diagnosis of HIV or other STIs, and/or use of HIV pre-exposure 366 prophylaxis because individual-level behavior data were not available; however, this limited the 367 researchers' ability to account for confounding. Health-seeking behavior, HIV status, geographic 368 location, socioeconomic status, race and gender identity are examples of other confounders which

369 were not considered or accounted for by some studies. Studies that actively recruited participants could obtain more detailed data on exposure risk but were also subject to bias based on factors 370 371 related to willingness to participate as well as recall bias. A test-negative case-control design, which 372 might help reduce selection bias and avoid confounding associated with health-seeking behavior 373 because cases and controls arise from the same source population, was employed in only one study 374 [28]. Concern was raised in a letter to the editor that immortal time bias and confounding might have 375 overestimated the adjusted VE of one dose of MVA-BN administered as PEP estimated by Montero 376 Morales et al. (89% [95% CI 76-95]) [31, 48]. In their response letter, Montero Morales et al. 377 performed an intent-to-treat analysis and found a VE of 75% (95% CI 55-86). Additionally, they 378 performed a landmark approach analysis to try and account for immortal time bias by including 379 vaccination as a time-varying exposure, which resulted in an estimated VE of 83% (95% CI 61-92) 380 [49]. The importance of being mindful of immortal time bias was also demonstrated by the target trial 381 emulation conducted by Rosen et al. [24], which lowered their adjusted VE estimates against 382 symptomatic infections for PEP administered ≤14 days after last exposure from 78% (95% CI 50–91) 383 to 19% (95% CI -54–57). Regardless of these limitations and the heterogeneity in study design and 384 methods across the included studies, the VE estimates of MVA-BN against symptomatic mpox 385 infection were generally high and in similar ranges. Taken together, the available real-world VE data 386 support the use of MVA-BN in managing active outbreaks.

Future VE studies may be conducted if new outbreaks continue to expand. Ideally, investigators would prioritize maximizing comparability in risk of exposure/infection over time in the vaccinated and unvaccinated and in cases and controls in order to generate a more precise estimate of the true effectiveness of MVA-BN against mpox.

391 **Conclusions**

Despite heterogeneity in study design, study settings, and at-risk populations across the 16 included studies, this SLR demonstrated the effectiveness of one or two doses of MVA-BN against symptomatic mpox infection in outbreak settings. As such, the presented data support the deployment of MVA-BN for mpox outbreak control. The identified methodological limitations and biases underscore the need for improved study designs to allow more accurate evaluation and more precise estimation of the true effectiveness of MVA-BN against mpox.

398 Additional information

399 Acknowledgments

400 The authors thank Lotte Mathé (P95) for medical writing support.

401 Author contributions

- 402 FL: Conceptualization; Writing review and editing
- 403 SS: Conceptualization; Writing review and editing
- 404 EB: Investigation; Writing original draft; Writing review and editing
- 405 LM: Investigation; Writing original draft; Writing review and editing
- 406 MRM: Conceptualization; Supervision; Writing review and editing

407 Availability of data

408 Other: All data used in this study originated from published sources.

409 Conflicts of interest

- 410 FL and SS are employees of Bavarian Nordic. The study-related activities of P95 employees EB, LM,
- 411 and MRM were funded by Bavarian Nordic. All authors attest that they meet the ICMJE criteria for
- 412 authorship.

413 Funding source

- 414 The research presented in this manuscript and manuscript development were funded by Bavarian
- 415 Nordic Inc.

416 **References**

417	1.	Petersen, B.W., et al., Vaccinating against monkeypox in the Democratic Republic of the
418		Congo. Antiviral Res, 2019. 162: p. 171-177. https://doi.org/10.1016/j.antiviral.2018.11.004
419	2.	Huang, Y., Mu, L., and Wang, W., Monkeypox: epidemiology, pathogenesis, treatment and
420		prevention. Signal Transduct Target Ther, 2022. 7(1): p. 373. https://doi.org/10.1038/s41392-
421		<u>022-01215-4</u>
422	3.	Sharma, A., et al., Monkeypox epidemiology, clinical presentation, and transmission: a
423		systematic review. Int J Emerg Med, 2023. 16(1): p. 20. https://doi.org/10.1186/s12245-023-
424		<u>00491-3</u>
425	4.	Durski, K.N., et al., Emergence of Monkeypox - West and Central Africa, 1970-2017. MMWR
426		Morb Mortal Wkly Rep, 2018. 67(10): p. 306-310. <u>https://doi.org/10.15585/mmwr.mm6710a5</u>
427	5.	Thornhill, J.P., et al., Monkeypox Virus Infection in Humans across 16 Countries - April-June
428		2022. N Engl J Med, 2022. 387(8): p. 679-691. <u>https://doi.org/10.1056/NEJMoa2207323</u>
429	6.	World Health Organization. 2022-23 Mpox Outbreak: Global Trends. 2023 [cited 2024 Mar
430		22]; Available from: https://worldhealthorg.shinyapps.io/mpx_global/.
431	7.	Reed, K.D., et al., The detection of monkeypox in humans in the Western Hemisphere. N
432		Engl J Med, 2004. 350 (4): p. 342-50. <u>https://doi.org/10.1056/NEJMoa032299</u>
433	8.	Perez Duque, M., et al., Ongoing monkeypox virus outbreak, Portugal, 29 April to 23 May
434		2022. Euro Surveill, 2022. 27(22). <u>https://doi.org/10.2807/1560-7917.ES.2022.27.22.2200424</u>
435	9.	Mitja, O., et al., <i>Monkeypox.</i> Lancet, 2023. 401 (10370): p. 60-74.
436		https://doi.org/10.1016/S0140-6736(22)02075-X
437	10.	Centers for Disease Control and Prevention. 2023 Outbreak in Democratic Republic of
438		Congo. 2024 [cited 2024 Mar 25]; Available from:
439		https://www.cdc.gov/poxvirus/mpox/outbreak/2023-drc.html.
440	11.	World Health Organization. Disease Outbreak News; Mpox (monkeypox) in the Democratic
441		Republic of the Congo. 2023 [cited 2024 Apr 4]; Available from:
442		https://www.who.int/emergencies/disease-outbreak-news/item/2023-DON493.
443	12.	Volkmann, A., et al., The Brighton Collaboration standardized template for collection of key
444		information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform.
445		Vaccine, 2021. 39 (22): p. 3067-3080. <u>https://doi.org/10.1016/j.vaccine.2020.08.050</u>

- 13. Centers for Disease Control and Prevention. Mpox Vaccination. 2023 [cited 2024 Mar 22];
- 447 Available from: <u>https://www.cdc.gov/poxvirus/mpox/interim-considerations/overview.html</u>.
- 448 14. European Medicines Agency. *Imvanex*. 2023 [cited 2024 Mar 22]; Available from:
- 449 https://www.ema.europa.eu/en/medicines/human/EPAR/imvanex.
- 450 15. Government of Canada. Smallpox and mpox (monkeypox) vaccines: Canadian Immunization
- 451 Guide. 2023 [cited 2024 Mar 22]; Available from: https://www.canada.ca/en/public-
- 452 <u>health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-</u>
- 453 vaccines/page-21-smallpox-vaccine.html.
- UK Health Security Agency. *Guidance Protecting you from mpox (monkeypox): information*on the smallpox vaccination. 2022 [cited 2024 Mar 22]; Available from:
- 456 https://www.gov.uk/government/publications/monkeypox-vaccination-resources/protecting-
- 457 <u>you-from-monkeypox-information-on-the-smallpox-vaccination</u>.
- 458 17. U.S. Food & Drug Administration. Jynneos. 2023 [cited 2024 Mar 22]; Available from:
- 459 https://www.fda.gov/vaccines-blood-biologics/jynneos.
- 460 18. Page, M.J., et al., The PRISMA 2020 statement: an updated guideline for reporting
- 461 systematic reviews. BMJ, 2021. **372**: p. n71. <u>https://doi.org/10.1136/bmj.n71</u>
- 462 19. Moher, D., et al., Preferred reporting items for systematic review and meta-analysis protocols
- 463 (PRISMA-P) 2015 statement. Syst Rev, 2015. 4(1): p. 1. https://doi.org/10.1186/2046-4053-4-
- 464

- 465 20. Dalton, A.F., et al., Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A
- 466 Multijurisdictional Case-Control Study United States, August 19, 2022-March 31, 2023.
- 467 MMWR Morb Mortal Wkly Rep, 2023. **72**(20): p. 553-558.
- 468 <u>https://doi.org/10.15585/mmwr.mm7220a3</u>
- 469 21. Deputy, N.P., et al., *Vaccine Effectiveness of JYNNEOS against Mpox Disease in the United*470 States. N Engl J Med, 2023. 388(26): p. 2434-2443. https://doi.org/10.1056/NEJMoa2215201
- 471 22. Payne, A.B., et al., *Reduced Risk for Mpox After Receipt of 1 or 2 Doses of JYNNEOS*
- 472 Vaccine Compared with Risk Among Unvaccinated Persons 43 U.S. Jurisdictions, July 31-
- 473 October 1, 2022. MMWR Morb Mortal Wkly Rep, 2022. **71**(49): p. 1560-1564.
- 474 <u>https://doi.org/10.15585/mmwr.mm7149a5</u>

- 475 23. Ramchandani, M.S., et al., Effectiveness of the Modified Vaccinia Ankara Vaccine Against
- 476 Mpox in Men Who Have Sex With Men: A Retrospective Cohort Analysis, Seattle,
- 477 Washington. Open Forum Infect Dis, 2023. 10(11): p. ofad528.
- 478 https://doi.org/10.1093/ofid/ofad528
- 479 24. Rosen, J.B., et al., JYNNEOS effectiveness as post-exposure prophylaxis against mpox:
- 480 Challenges using real-world outbreak data. Vaccine, 2024. **42**(3): p. 548-555.
- 481 <u>https://doi.org/10.1016/j.vaccine.2023.12.066</u>
- 482 25. Rosenberg, E.S., et al., *Effectiveness of JYNNEOS Vaccine Against Diagnosed Mpox*
- 483 Infection New York, 2022. MMWR Morb Mortal Wkly Rep, 2023. 72(20): p. 559-563.
- 484 <u>https://doi.org/10.15585/mmwr.mm7220a4</u>
- 485 26. Schildhauer, S., et al., Reduced Odds of Mpox-Associated Hospitalization Among Persons
- 486 Who Received JYNNEOS Vaccine California, May 2022-May 2023. MMWR Morb Mortal
- 487 Wkly Rep, 2023. 72(36): p. 992-996. https://doi.org/10.15585/mmwr.mm7236a4
- Allard, R., et al., *Breakthrough cases of mpox: One-dose vaccination is associated with milder clinical manifestations.* J Infect Public Health, 2024. **17**(4): p. 676-680.
- 490 <u>https://doi.org/10.1016/j.jiph.2024.02.015</u>
- 491 28. Brousseau, N., et al., Single-dose Effectiveness of Mpox Vaccine in Quebec, Canada: Test-
- 492 negative Design With and Without Adjustment for Self-reported Exposure Risk. Clin Infect Dis,
- 493 2024. 78(2): p. 461-469. https://doi.org/10.1093/cid/ciad584
- 494 29. Navarro, C., et al., *Effectiveness of one dose of MVA-BN vaccine against mpox infection in*
- 495 males in Ontario, Canada: A target trial emulation. 2023.
- 496 <u>https://doi.org/doi:10.1101/2023.10.04.23296566</u>
- 497 30. Fontan-Vela, M., et al., *Effectiveness of Modified Vaccinia Ankara-Bavaria Nordic Vaccination*498 *in a Population at High Risk of Mpox: A Spanish Cohort Study.* Clin Infect Dis, 2024. **78**(2): p.
- 499 476-483. <u>https://doi.org/10.1093/cid/ciad645</u>
- 500 31. Montero Morales, L., et al., *Post-exposure vaccine effectiveness and contact management in*
- 501 the mpox outbreak, Madrid, Spain, May to August 2022. Euro Surveill, 2023. 28(24).
- 502 https://doi.org/10.2807/1560-7917.ES.2023.28.24.2200883

- 503 32. Bertran, M., et al., Effectiveness of one dose of MVA-BN smallpox vaccine against mpox in
- 504 England using the case-coverage method: an observational study. Lancet Infect Dis, 2023.
- 505 **23**(7): p. 828-835. <u>https://doi.org/10.1016/S1473-3099(23)00057-9</u>
- 33. Charles, H., et al., Post-peak mpox in England: epidemiology, reinfection, and vaccine
- 507 effectiveness data from 2023. medRxiv, 2024: p. 2024.02.26.24303362.
- 508 https://doi.org/10.1101/2024.02.26.24303362
- 509 34. Wolff Sagy, Y., et al., *Real-world effectiveness of a single dose of mpox vaccine in males.* Nat
- 510 Med, 2023. **29**(3): p. 748-752. <u>https://doi.org/10.1038/s41591-023-02229-3</u>
- 511 35. Haverkate, M.R., et al., Factors that influenced the course of the mpox outbreak in the
- 512 *Netherlands, 2022-2023.* medRxiv, 2023: p. 2023.10.09.23296426.
- 513 https://doi.org/10.1101/2023.10.09.23296426
- 514 36. Fine, P.E., et al., The transmission potential of monkeypox virus in human populations. Int J
- 515 Epidemiol, 1988. **17**(3): p. 643-50. <u>https://doi.org/10.1093/ije/17.3.643</u>
- 37. Arbel, R., Zucker, R., and Wolff-Sagy, Y., *Vaccine Effectiveness against Mpox in the United*517 States Letter to the Editor. N Engl J Med, 2023. 389(15): p. 1440.
- 518 https://doi.org/10.1056/NEJMc2309583
- 519 38. Deputy, N.P.G., J.L., Vaccine Effectiveness against Mpox in the United States Author's reply.
- 520 New England Journal of Medicine, 2023. **389**(15): p. 1440-1441. <u>https://doi.org/DOI</u>:
- 521 10.1056/NEJMc2309583
- Hatch, G.J., et al., Assessment of the protective effect of Imvamune and Acam2000 vaccines
 against aerosolized monkeypox virus in cynomolgus macagues. J Virol, 2013. 87(14): p.
- 524 7805-15. https://doi.org/10.1128/JVI.03481-12
- 40. Pittman, P.R., et al., *Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against*Smallpox. N Engl J Med, 2019. **381**(20): p. 1897-1908.
- 527 https://doi.org/10.1056/NEJMoa1817307
- 528 41. Ilchmann, H., et al., One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-
- 529 Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating
- 530 Smallpox Vaccines. J Infect Dis, 2023. 227(10): p. 1203-1213.
- 531 https://doi.org/10.1093/infdis/jiac455

- 42. Hubert, M., et al., Complement-dependent mpox-virus-neutralizing antibodies in infected and
- 533 vaccinated individuals. Cell Host Microbe, 2023. **31**(6): p. 937-948 e4.

534 https://doi.org/10.1016/j.chom.2023.05.001

- 43. Mazzotta, V., et al., Immunogenicity and reactogenicity of modified vaccinia Ankara pre-
- 536 exposure vaccination against mpox according to previous smallpox vaccine exposure and
- 537 *HIV infection: prospective cohort study.* EClinicalMedicine, 2024. **68**: p. 102420.
- 538 https://doi.org/10.1016/j.eclinm.2023.102420
- 539 44. Wyatt, L.S., et al., *Highly attenuated smallpox vaccine protects mice with and without immune*
- 540 *deficiencies against pathogenic vaccinia virus challenge.* Proc Natl Acad Sci U S A, 2004.
- 541 **101**(13): p. 4590-5. <u>https://doi.org/10.1073/pnas.0401165101</u>
- 542 45. Cohn, H., et al., Mpox vaccine and infection-driven human immune signatures: an
- 543 *immunological analysis of an observational study.* Lancet Infect Dis, 2023. 23(11): p. 1302-
- 544 1312. <u>https://doi.org/10.1016/S1473-3099(23)00352-3</u>
- Freyn, A.W., et al., *An mpox virus mRNA-lipid nanoparticle vaccine confers protection against lethal orthopoxviral challenge.* Sci Transl Med, 2023. **15**(716): p. eadq3540.
- 547 https://doi.org/10.1126/scitranslmed.adg3540
- 548 47. Robert Koch-Institut. *Mpox Impfmonitoring Juni 2022 Januar 2024*. 2024 [cited 2024 18
- 549 Apr]; Available from:
- 550 https://www.rki.de/DE/Content/Infekt/Impfen/ImpfungenAZ/Affenpocken/Affenpocken-
- 551 Impfmonitoring.pdf?__blob=publicationFile.
- 48. van Ewijk, C.E. and Hahne, S.J., Letter to the editor: Bias in the vaccine effectiveness
- 553 estimates of one-dose post-exposure prophylaxis against mpox. Euro Surveill, 2023. 28(34).
- 554 <u>https://doi.org/10.2807/1560-7917.ES.2023.28.34.2300358</u>
- 49. Montero Morales, L., et al., *Authors' response: Bias in the vaccine effectiveness estimates of*
- 556 one-dose post-exposure prophylaxis against mpox. Euro Surveill, 2023. **28**(34).
- 557 https://doi.org/10.2807/1560-7917.ES.2023.28.34.2300442

559 Tables

560 Table 1. Characteristics of the studies included

Author, date Country	Study design Period	Study population Setting	Sample size, n ^a	Vaccination strategy ^b	VE analyses
Allard, 2024 [27]	Retrospective cohort study	Individuals with mpox Public health surveillance from	403	PrEP ± PEP	VE calculated as: 1 - odds of clinical outcomes among persons with mpox who were vaccinated compared with
Canada	19 May 2022 to 2023 [°]	Montreal Public Health; supplemented with self-reported sociodemographic and clinical data from questionnaires; vaccination data from provincial immunization registry			 those who were unvaccinated By time after vaccination By clinical manifestations^d
Bertran, 2023 [32]	Case- coverage	Mpox cases; vaccine coverage estimated in at-risk GBMSM population	Cases: 363 Population used for coverage	PrEP	VE calculated as: 1 - odds of vaccination in cases/odds of vaccination in the population
United Kingdom	04 Jul 2022 to 21 Dec 2022	Cases: public health surveillance data from across England, with self- reported vaccination data from questionnaires; coverage population in England estimated by public health agency (no individual patient-level data)	estimate: 89,240		 By time after vaccination; all ages By time after vaccination; cases younger than 50 years
Brousseau, 2023 [28]	Test-negative case-control	Individuals with a specimen submitted for mpox testing	Cases: 231 Controls: 301	PrEP	VE calculated as: 1 - odds of vaccination in cases/odds of vaccination in the population
Canada	19 Jun 2022 to 24 Sep 2022	Public health surveillance data from the province of Quebec, linked to administrative data and supplemented with self-reported sociodemographic and exposure data from questionnaires	Subset with questionnaire data: 199		 For entire sample For subset with questionnaire data For subset with questionnaire data, adjusting for questionnaire variables

Charles, 2024 [33] United Kingdom	Case- coverage 01 Jan 2023 to 31 Dec 2023	Confirmed positive or highly probable mpox case; vaccine coverage estimated in at-risk GBMSM population in England Cases: public health surveillance data from across England; aggregate mpox vaccination data obtained from the NHS England	Cases: 137 Population used for coverage estimate: 89,240	PrEP	VE calculated as: 1 - odds of vaccination in cases/odds of vaccination in the population • By dose (one or two)
Dalton, 2023 [20] United States	Case-control 19 Aug 2022 to 31 Mar 2023	Mpox cases; controls were MSM/transgender adults visiting sexual health/HIV care/HIV pre- exposure prophylaxis clinics Cases: Public health surveillance data from 12 US jurisdictions; controls identified from public health clinics; self-reported vaccination data from surveys verified by state registries where available	Cases: 309 Controls: 608	PrEP ± PEP ^e	 VE calculated as: 1 - odds of vaccination among cases/odds of vaccination among controls By dose (one or two) By route of administration By IC status
Deputy, 2023 [21] United States	Case-control 15 Aug 2022 to 19 Nov 2022	Mpox cases; Controls with incident HIV infection or taking HIV pre- exposure prophylaxis Inpatient and outpatient electronic health data aggregated from healthcare systems across the US; Cosmos Epic database	Cases: 2,193 Controls: 8,319	PrEP	VE calculated as: 1 - odds of vaccination among cases/odds of vaccination among controls • By dose (one or two) • By route of administration • Non-IC only • Male only • Without previous smallpox vaccination
Fontán-Vela, 2023 [30] Spain	Retrospective cohort study 12 Jul 2022 to 12 Dec 2022	Men receiving HIV pre-exposure prophylaxis Public health surveillance data from autonomous regions across Spain	11,320	PrEP	 VE calculated as: 1 - risk of infection among vaccinated group/risk of infection among unvaccinated group By time since vaccination; all ages By time since vaccination; among individuals under 50 years

Haverkate, 2023 [35] The Netherlands	Case- coverage 08 Aug 2022 to 04 Dec 2022	Mpox cases; vaccine coverage calculated in population invited for vaccination (GBMSM/transgender persons using/on the waiting list for HIV pre-exposure prophylaxis or at high risk for mpox) Public health institutions across the Netherlands	Cases: 162 Population for coverage calculation: 39,657	PrEP ± PEP ^e	VE calculated as 1 - odds of vaccination in cases/odds of vaccination in the population
Montero Morales, 2023 [31] Spain	Prospective cohort 17 May 2022 to 15 Aug 2022	Close contacts of laboratory- confirmed mpox cases Public health institutions serving the Madrid region; confirmed by vaccination registries	484	PEP	 VE calculated as 1 - hazard rate among vaccinated group/hazard rate among unvaccinated group By time from exposure to vaccination By clinical symptoms (general symptoms^f or polysymptomatic disease⁹) By age By sex By contact type By HIV-related information
Navarro, 2023 [29] Canada	Prospective cohort 12 Jun 2022 to 26 Nov 2023	Individuals with at least one syphilis test in the previous year, a new diagnosis of one or more bacterial STIs in the previous year or who filled a prescription for HIV pre- exposure prophylaxis in the previous year Public health surveillance data from	6,408 (3,204 vaccinated individuals matched with 3,204 unvaccinated individuals)	PrEP	VE calculated as 1 - hazard rate among vaccinated group/hazard rate among unvaccinated group • By time after vaccination

Payne, 2022 [22] United States	Case- coverage 31 Jul 2022 to 01 Oct 2022	Mpox cases; vaccine coverage estimated in MSM with HIV or eligible for HIV pre-exposure prophylaxis Cases: Public health surveillance data from 43 jurisdictions across the US; coverage population of MSM/HIV pre-exposure prophylaxis recipients estimated (no individual patient-level data)	Cases: 9,544 Population used for coverage estimate: NR	PrEP ± PEP	Incidence rate ratio was calculated comparing that of unvaccinated individuals to vaccinated individuals with one or two doses
Ramchandani , 2023 [23] United States	Retrospective cohort 01 May 2022 to 31 Dec 2022	MSM attending sexual health clinics Public health institutions, vaccination registries and surveillance data from Seattle and King Country, Washington	204 mpox cases 4,230 MSM attended the clinic	PrEP ± PEP	 VE calculated as 1 - hazard rate among vaccinated group/hazard rate among unvaccinated group By dose (one or two)
Rosen, 2024 [24] United States	Retrospective cohort study 22 May 2022 to 24 Aug 2022	Individuals exposed to persons with confirmed mpox Public health surveillance data from the New York City Department of Health and Mental Hygiene	PEP _L ^h : 594 PEP _F ^h : 471	PEP	 VE calculated as 1 - adjusted odds among vaccinated group/odds among unvaccinated group By time from first and last exposure to vaccination By method; target trial emulation or conventional
Rosenberg, 2023 [25] United States	Case-control 02 Jun 2022 to 31 Dec 2022	Mpox cases; controls were males with rectal gonorrhea or primary syphilis diagnosed within the same time frame as the mpox cases, and with presumptive sexual contact with a male or transgender person Public health surveillance data covering New York State (excluding NYC); CDESS	Cases:252 Controls: 255	PrEP ± PEP	 VE calculated as: 1 - odds of vaccination among cases/odds of vaccination among controls By dose (one, two or both) By time intervals after receipt of one or two doses

Schildhauer,	Retrospective	California residents diagnosed with	250 mpox-	PrEP ± PEP	Odds of hospitalization among persons
2023 [26]	cohort	mpox	associated hospitalizations		with mpox who were vaccinated compared with those who were
	12 May 2022	Public health surveillance data	4,611 persons		unvaccinated were calculated
United States	2023		with mpox		 By dose (one or two) By strategy (PEP or PrEP) By HIV status By dose and HIV status By strategy and HIV status
Wolff Sagy, 2023 [34]	Retrospective cohort	Males aged 18–42 years who were (a) dispensed HIV pre-exposure prophylaxis at least for 1 month since	2,054	PrEP ± PEP	VE calculated as 1 - hazard rate among vaccinated group/hazard rate among unvaccinated group
Israel	31 Jul 2022 to 25 Dec 2022	1 January 2022, or (b) diagnosed with HIV and also were diagnosed with one or more STIs since 1 January 2022 HER database from a large healthcare system operating across Israel (52% of population covered); CHS			

CDESS: The Communicable Disease Electronic Surveillance System; CHS: Clalit Health Services; GBMSM: gay, bisexual, and other men who have sex with men; HIV: human immunodeficiency virus; IC: immunocompromised; MSM: men who have sex with men; NHS: National Health Service; NYC: New York City; PEP: post-exposure prophylactic vaccination; PEP: post-exposure prophylactic vaccination; PrEP: pre-exposure prophylactic vaccination; STI: sexually transmitted infection; US: United States; VE: vaccine effectiveness.

^a Sample size as used in the main VE analysis; ^b The studies focused either on PrEP or on PEP. In the former case, studies may have inadvertently included some PEP recipients and these studies are designated as 'PrEP \pm PEP'; ^c The mpox outbreak in Montreal, Canada, during 2022; ^d The number of lesions, sites affected by lesions, and other clinical manifestations (OCM); ^e Number of participants receiving MVA-BN as PEP limited by exclusion of those receiving the vaccine \leq 13 days before their index date. VE for PEP was not estimated due to small sample sizes; ^f General symptoms: exanthema, lymphadenopathy, proctitis, mouth ulcers, ocular involvement, bacterial superinfection of lesions, bronchopneumonia, and general symptoms such as fever, asthenia, odynophagia, muscle pain, headache, other); ^g Polysymptomatic disease: Four or more symptoms described in 'general symptoms'. ^h Analyses of VE were conducted separately for MVA-BN vaccine administered as PEP \leq 14 days after the last exposure (PEP_L) and for PEP administered \leq 14 days after the first exposure (PEP_F).

Table 2. Vaccine effectiveness estimates against symptomatic mpox disease ≥14 days after vaccination for MVA-BN administered

563 exclusively or primarily as pre-exposure prophylactic vaccination

Author, date Study design	Study population	Sample size, n	Crı (95	Crude VE Adjusted VE (95% Cl) (95% Cl)		Adjusted VE Statistical methods (95% CI)	
			One dose	Two doses	One dose	Two doses	
PrEP							
Bertran, 2023 [32] Case-coverage	Mpox cases; vaccine coverage estimated in at-risk GBMSM population	Cases: 330 Population used for coverage estimate: 89,240	78% (54–89)	NR	NR	NR	Basic rate comparison without adjustment
Brousseau, 2023 [28]	Individuals with a specimen submitted for mpox testing	Cases: 231 Controls: 301	33% (2–54)	NR	35% (-2–59)	NR	Logistic regression Adjustment for age, calendar time, STI tests and diagnosis, HIV status
case-control	Subset with questionnaire data	Cases: 91 Controls: 108	38% (-9–65)	NR	30% (-38–64)	NR	Logistic regression Adjustment for age, calendar time, STI tests and diagnosis, HIV status
			NR	NR	65% (1–87)	NR	As above, additionally adjusted for ethnocultural background, immunosuppression, HIV status/pre-exposure prophylaxis use, contact with a person who has mpox symptoms, number of sexual partners, drug use before or during sexual activity, sex involving >2 people, attending sex-on-premise venues, skin-to- skin contacts during a festive event
Charles, 2024 [33]	Confirmed positive or highly probable mpox case; vaccine	Cases: 126 Population used for coverage	84% (74–91)	80% (69–83) ^a	NR	NR	Basic rate comparison without adjustment

Case-coverage	coverage estimated in at-risk GBMSM	estimate: 89,240					
Deputy, 2023	Mpox cases; Controls	One dose	52%	77%	36%	66%	Conditional logistic regression
[21] Case-control	with incident HIV infection or taking HIV pre-exposure prophylaxis	Cases: 2,168 Controls: 7,984 <u>Two doses</u> Cases: 2,047	(42–60)	(65–85)	(22–47)	(47–78)	Adjustment for age, race or ethnic group, SVI score, and the presence or absence of IC conditions
	· · · · · · · · · · · · · · · · · · ·	Controls: 7,319					
Fontán-Vela, 2023 [30]	Men receiving HIV pre-exposure prophylaxis	Exposed: 5,560 Unexposed: 5,560	79% (33– 100)	NR	NR	NR	Basic rate comparison without adjustment
Retrospective cohort							
Navarro, 2023 [29] Prospective cohort	Individuals with at least one syphilis test in the previous year, a new diagnosis of one or more bacterial STIs in the previous year or who filled a prescription for HIV pre-exposure prophylaxis in the previous year	Exposed: 3,204 Unexposed: 3,204	NR	NR	59% (31–76)	NR	Cox proportional hazards model Adjustment for age, geographic region, proxies for sexual exposures (number of bacterial STIs in the previous three years, HIV status), and history of receipt of any non-MVA-BN vaccine in the previous year
PrEP ± PEP [*]	Moox casos: controls	Ono doso:	76%	97%	75%	86%	Conditional logistic regression
[20]	Mpox cases, controls were MSM/transgender	Cases: 281 Controls: 430	(65–83)	(79–93)	(61–84)	00% (74–92)	Adjustment for age, race, and
Case-control	adults visiting sexual health/HIV care/HIV pre-exposure prophylaxis clinics	<u>Two doses</u> : Cases: 251 Controls: 371					conditions; and close contact with a person with known mpox
Haverkate, 2023	Mpox cases; vaccine coverage calculated	Cases: 162 Population for	NR	68% (4–90)	NR	NR	A logistic regression model + with the logit of the proportion of the

[35] Case-coverage	in population invited for vaccination (GBMSM/transgender persons using/on the waiting list for HIV pre-exposure prophylaxis or at high risk for mpox)	coverage calculation: 39,657					population vaccinated as an offset
Payne, 2022 [22] Case-coverage	Mpox cases; vaccine coverage estimated in MSM with HIV or eligible for HIV pre- exposure prophylaxis	One dose: Cases: 8,712 Population used for coverage estimate: NR <u>Two doses</u> : Cases: 48 Population used for coverage estimate: NR	NR	NR	86% (83–89) [°]	90% (86–92) [°]	IRR: negative binomial regression, controlling for week
Ramchandani, 2023 [23] Retrospective cohort	MSM attending sexual health clinics	Exposed: 1837 Nonexposed: 2,393	60% (24–79)	57% (-84–90)	81% (64–90)	83% (28–96)	Cox proportional hazards model Adjustment for age, race/ethnicity, HIV status, year of last SHC visit, methamphetamine use in the last year, gonorrhea or syphilis diagnosis in the last year, and self-report of >10 sex partners in the last year
Rosenberg, 2023 [25] Case-control	Mpox cases; controls were males with rectal gonorrhea or primary syphilis diagnosed within the same time frame as the mpox cases, and with presumptive sexual contact with a male or transgender person	<u>One dose</u> : Cases: 240 Controls: 227 <u>Two doses:</u> Cases:232 Controls: 223	NR	NR	68% (25–87)	89% (44–98) ^d	Conditional logistic regression Adjustment for age, race, and ethnicity; and region within New York outside NYC

Wolff Sagy, 2023	Individuals considered at high	Exposed: 1,037 Unexposed:	NR	NR	86% (59–95) ^e	NR	Multivariate cox proportional hazards regression
[34] Retrospective cohort	risk for infection and eligible for the vaccine	1,017					Adjustment for age, sex, sector, sociodemographic status, MVA- BN vaccine uptake, Tel Aviv District, HIV pre-exposure prophylaxis use, purchase of PDE5 inhibitors, HIV history, STI (chlamydia or gonorrhea, recent
							chlamydia or gonorrhea)

CI: confidence interval; GBMSM: gay, bisexual, and other men who have sex with men; HIV: human immunodeficiency virus; IC: immunocompromised;

MSM: men who have sex with men; NR: not reported; NYC: New York City; PDE5: phosphodiesterase 5; SHC: sexual health clinic; STI: sexually

transmitted infection; SVI: social vulnerability index; VE: vaccine effectiveness.

^a Includes one individual who reported having received three doses; ^b Studies that focused on PrEP but may have inadvertently included some PEP

recipients; ^c Calculated by the authors of this systematic literature review; ^d ≥ 0 days after the second dose; ^e Also includes cases <14 days after vaccination.

Table 3. Vaccine effectiveness estimates against symptomatic mpox disease ≥14 days after second dose for MVA-BN administered as

566 post-exposure prophylactic vaccination

Author, date Study design	Study population	Sample size, n	Crude VE % (95% Cl)		Adjusted VE (95% CI)		Statistical methods
			One dose	Two doses	One dose	Two doses	_
Montero	Close contacts of	Exposed: 230	84%	NR	89% (76, 95) ^a	NR	Survival analysis
[31] Prospective	confirmed mpox cases	Unexposed. 204	(00-92)		(70-33)		Adjustment for age, sex, type of close contact, HIV pre-exposure prophylaxis user, HIV infection, and
cohort study		b	· · ·	8 8 9 M			symptoms
Rosen, 2024 [24]	Individuals having contact with persons with	PEPL ^o Exposed: 333 Unexposed: 261	NR	NR	Conventional: PEP _{L:} 78% (50–91)	NR	Conventional: multivariate logistic regression, controlling for exposure risk and race/ethnicity
Retrospective cohort study – with target trial design	confirmed mpox	PEP _F ^b Exposed: 183 Unexposed: 288			PEP _F : 73% (31–91)		Target trial emulation: sequence of nested trials starting each day after exposure to account for immortal time
					Target trial PEP _L : 19% (-54–57)		bias. Logistic regression controlling for exposure risk and race/ethnicity
					PEP _F : -7% (-144–53)		

CI: confidence interval; HIV: human immunodeficiency virus; NR: not reported; PEP: post-exposure prophylaxis; VE: vaccine effectiveness.

^a Also includes cases <14 days after vaccination; ^b Analyses of VE were conducted separately for MVA-BN vaccine administered as PEP ≤14 days after the

last exposure (PEP_L) and for PEP administered \leq 14 days after the first exposure (PEP_F).

568 Table 4. Vaccine effectiveness estimates against hospitalizations and mpox clinical manifestations

Author, date Study design	Study population	Sample size, n	Crude VE (95% Cl)	Adjusted VE (95% Cl)	Statistical methods
Hospitalizations					
Schildhauer, 2023	dhauer, 2023 One dose of MVA-BN, ≥14 days after vaccination				Binomial logistic regression
[26]	California residents	Exposed: 230	73% (35–92) ^a	NR	
	diagnosed with	Unexposed: 3,845			
Retrospective	mpox				
cohort	Two doses of MVA-BN, ≥14 days after 2nd dose				
	California residents	Exposed: 79	80% (10–99) ^a	NR	
	diagnosed with mpox	Unexposed: 3,845			
	One dose of MVA-BN after a known or suspected exposure, <14 days				_
	after vaccination		F00/ (00 70)a		_
	California residents	Exposed: 457	58% (28-78)*	NR	
	diagnosed with	Unexposed: 3,845			
Clinical manifestati	inpox				
Allard 2024 Numbers of skin losions at day 1 (one does) ^b					Multivariata logistia regression
Allalu, 2024 [27]	Individuals with	Expand: 50		600/ (21 00)	
[27]	moov	Exposed: 39	INIT	00% (Z1 - 00)	Adjustment for each other
Retrospective	Body sites affected at day 1 (one dose) ^b				 clinical manifestation and age
cohort	Individuals with	Exposed: 50	ND	760/ (5/ 07)	_
oonon	mooy	Exposed: 344	INIT	76% (34–67)	
		Ullexposed. 344			_
		Exposed: 50	ND	50% (26 77)	_
	mooy	Exposed: 344		59% (20-77)	
Montero Morales	General symptoms	(one dose PEP)			Survival analysis
2023	General symptoms	Expand: 220	60 00/	71 60/	
[31]	laboratory	Exposed: 250	(-1, 5, 00, 4)	(18 1 00 2)	Adjustment for age, sex, type of
[51]	confirmed mpoy	Ullexposed. 234	(-1.3-90.4)	(10.1-90.2)	close contact, HIV pre-exposure
Prospective					prophylaxis user and HIV
cohort	 Polysymptomatic disease ^e (one dose PEP)				 infection
oonon	Close contacts of Exposed: 230 87.5% 85.5%				—
	laboratory-	Linexposed: 254	(6.2-98.3)	(26 7-91 1)	
	confirmed mnov	016700360. 204	(0.2-30.3)	(20.7-31.1)	
	cases				

CI: confidence interval; HIV: human immunodeficiency virus; NR: not reported; PEP: post-exposure prophylactic vaccination; VE: vaccine effectiveness.

^a Calculated by the authors of this systematic literature review; ^b Vaccine administered ≥14 days before the onset of symptoms; ^c Other clinical manifestations (OCM): fever, adenopathy, fatigue, muscle pains, headaches, backaches, sweating, rectal pain, nausea and vomiting, sore throat etc. ^d General symptoms: fever, asthenia, odynophagia, muscle pain, headache, other; ^e Polysymptomatic disease: four or more symptoms described in 'general symptoms'.

570 Figure captions

571 Figure 1. PRISMA flowchart

572 DE: data extraction; FT: full-text review

